Discover
Humira (adalimumab) / Eisai, AbbVie; bimekizumab (UCB4940) / UCBA Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Apr 3, 2020 - P3; N=480; Completed; Sponsor: UCB Biopharma S.P.R.L.; Active, not recruiting --> Completed
piclidenoson (CF101) / Can-Fite, China Medical SystemCan-Fite implements interim analysis for its phase III psoriasis trial with data expected Q4 2020 (Businesswire) - Mar 30, 2020 - "Can-Fite BioPharma Ltd....announced today it is implementing an interim analysis of the Phase III Comfort™ trial designed to evaluate the Company’s drug candidate, Piclidenoson, in the treatment of moderate-to-severe plaque psoriasis. Following the independent data monitoring committee’s evaluation of the data, Can-Fite expects to announce interim results in the fourth quarter of 2020."
piclidenoson (CF101) / Can-Fite, China Medical SystemCF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Mar 31, 2020 - P3; N=407; Active, not recruiting; Sponsor: Can-Fite BioPharma; Recruiting --> Active, not recruiting; Trial completion date: Dec 2020 --> Dec 2021; Trial primary completion date: Feb 2020 --> Feb 2021
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimTherapeutic Positioning (IPT) of atezolizumab and risankizumab [Google translation] (Acta Sanitaria) - Mar 31, 2020 - "The Spanish Agency for Medicines and Health Products ( AEMPS ) has published this Tuesday, March 31...Therapeutic Positioning Report IPT_7-2020-risankizumab-Skyrizi, by AbbVie, a drug that is authorized in the treatment of plaque psoriasis."
